DXCM vs GEHC
Dexcom and GE HealthCare, both Healthcare
GE HealthCare is the larger company at $28B against $28B. On trailing earnings GEHC is the cheaper of the two at a P/E of 17.5 against 35.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year DXCM returned +16% against +4.9% for GEHC. Ryufin's sector-relative Smart Score puts GEHC ahead, 9/10 against 8/10.
| Figure | DXCM | GEHC |
|---|---|---|
| Last close | $88.96 | $73.31 |
| Market cap | $28B | $28B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 35.3 | 17.5 |
| Dividend yield | n/a | 0.2% |
| 1-year return | +16% | +4.9% |
| 5-year return | -31% | n/a |
| Ryufin Smart Scoresector-relative, 1–10 | 8/10 | 9/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Dexcom
Revenue of $1.3B in Q2 2026, net income $249M. Its largest reported line is United States, 81% of the disclosed total.
GE HealthCare
Revenue of $5.1B in Q1 2026, net income $389M. Its largest reported line is AIS, 64% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.